• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Aptar Reports First Quarter 2025 Results

    5/1/25 5:03:00 PM ET
    $ATR
    Plastic Products
    Industrials
    Get the next $ATR alert in real time by email

    AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following first quarter results for the period ended March 31, 2025, as compared to the corresponding period of the last fiscal year.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501642213/en/

    Aptar Reports First Quarter 2025 Results

    Aptar Reports First Quarter 2025 Results

    First Quarter 2025 Highlights (compared to the prior year quarter)

    • Reported sales of $887 million, a 3% decrease, and reported net income of $79 million, a 5% decrease
    • Core sales were flat and adjusted EBITDA increased 3% from the prior year to $183 million
    • Adjusted EBITDA margin of 20.7%, with margin expansion of 120 basis points
    • Reported earnings per share of $1.17
    • Adjusted earnings per share of $1.20, excluding the impact of currency effects and change in tax rate, earnings per share would have increased 5%
    • Pharma's proprietary drug delivery systems* reported sales grew 2% and core sales grew 4% in the quarter
    • Returned approximately $110 million to shareholders, including $80 million of share repurchases

    "Our pharma and closures segments delivered solid results with increased product sales in the quarter. We saw growing demand for our dosing, dispensing and protection technologies across a number of end markets including central nervous system therapeutics, emergency medicines, weight and diabetes management, as well as food, beverage and personal care. We also returned about $110 million to shareholders through dividends and share repurchases, more than half a million shares were repurchased for $80 million," said Stephan B. Tanda, Aptar President and CEO.

    First Quarter Results

    For the quarter ended March 31, 2025, reported sales decreased 3% to $887.3 million compared to $915.4 million in the prior year. Core sales were flat with the prior year quarter.

    First Quarter Segment Sales Analysis

    (Change Over Prior Year)

     

    Aptar

    Pharma

    Aptar

    Beauty

    Aptar

    Closures

    Total AptarGroup

    Reported Sales Growth

    1%

    (7)%

    (5)%

    (3)%

    Currency Effects (1)

    2%

    4%

    3%

    3%

    Acquisitions

    0%

    0%

    0%

    0%

    Core Sales Growth

    3%

    (3)%

    (2)%

    0%

     

    (1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.

     

    Aptar Pharma's reported sales increased 1% and core sales increased 3% in the quarter, following core sales growth of 13% in the prior year period. The segment's positive results were driven by continued demand for proprietary drug delivery systems used for emergency medicines and central nervous system therapies, especially for depression and seizures, as well as asthma, COPD and ophthalmic treatments. Injectables faced a challenging comparison from the prior year quarter – core sales grew 54% in the first quarter of 2024, a catch-up period following an enterprise resource planning system implementation. Active material science core sales grew 11%, due to increased demand from diabetes protection technologies. Adjusted EBITDA margins grew 230 basis points in the quarter, with royalty revenues helping drive adjusted EBITDA margins to 34.8%.

    Aptar Beauty's reported sales decreased 7% and core sales were down 3% compared to the prior year quarter primarily due to lower prestige fragrance volumes. Sales for personal care and home care products continued to show strong growth but could not offset lower demand in certain beauty dispensing technologies. Market demand in China continues to improve progressively for beauty dispensing systems. Adjusted EBITDA margins decreased slightly, by 50 basis points, to 12.1% due primarily to lower prestige fragrance volumes.

    Aptar Closures' reported sales decreased 5% from the prior year quarter and core sales decreased 2%. The solid product sales growth in the quarter was offset by meaningfully lower tooling sales from the prior year period and unprofitable sales in Argentina that the company chose to no longer service during late 2024. Without these headwinds, core sales would have increased by 3%. Adjusted EBITDA margins improved to approximately 15.8%, expanding by 80 basis points.

    Aptar reported first quarter earnings per share of $1.17 compared to $1.23 reported a year ago. Adjusted earnings per share, excluding restructuring charges, acquisition costs, and the unrealized gains or losses on an equity investment, were $1.20 compared to the prior year period's adjusted earnings per share of $1.22, including comparable exchange rates. The first quarter effective tax rate was 26% compared to the prior year period's effective tax rate of 20%. The higher effective tax rate for the three months ended March 31, 2025 reflects the estimated impact of the temporary 2025 surtax enacted in France during the quarter and lower tax benefits from share-based compensation. The tax rate for 2024 also reflects tax incentives in certain non-U.S. jurisdictions from intellectual property development activities.

    * Proprietary Drug Delivery Systems includes prescription, consumer healthcare and digital health divisions.

     

    Outlook

    Regarding Aptar's outlook, Tanda stated, "We expect to build on our solid start to the year as we head into the second quarter, with positive contributions from all three segments. As a leader in dosing, dispensing and protection technologies, we are well positioned across a number of resilient end markets, including medications for chronic diseases and consumer staples that are relied upon by millions of people every day, even in uncertain economic conditions. In addition, our robust, long-standing, in-region for-region supply chain structure allows us to be agile and flexible in a dynamic marketplace."

    Aptar currently expects earnings per share for the second quarter of 2025, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $1.56 to $1.64. This guidance is based on an effective tax rate range of 19% to 21%, primarily due to a one-time tax benefit, with a comparable adjusted prior year effective tax rate of 24%. The earnings per share guidance range is based on current spot rates for all currencies.

    Cash Dividends and Share Repurchases

    As previously announced, Aptar's Board of Directors approved a quarterly cash dividend of $0.45 per share. The payment date is May 22, 2025, to stockholders of record as of May 1, 2025. During the first quarter, Aptar repurchased 548 thousand shares for $80 million. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.

    Open Conference Call

    There will be a conference call held on Friday, May 2, 2025 at 8:00 a.m. Central Time to discuss the company's first quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at investors.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.

    About Aptar

    Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has more than 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

    Presentation of Non-GAAP Information

    This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar's management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management's view, do not reflect Aptar's core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar's management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the company's routine activities, such as restructuring and acquisition costs.

    This press release contains forward-looking statements, including certain statements set forth under the "Outlook" section of this press release. Words such as "expects," "anticipates," "believes," "estimates," "future," "potential," "continues" and other similar expressions or future or conditional verbs such as "will," "should," "would" and "could" are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide including the invasion of Ukraine by the Russian military and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising input costs and certain supply chain disruptions; cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems; the availability of raw materials and components (particularly from sole sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; competition, including technological advances; significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures taken by impacted foreign countries; the execution of our fixed cost reduction initiatives, including our optimization initiative; our ability to successfully implement facility expansions and new facility projects; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs; significant fluctuations in foreign currency exchange rates or our effective tax rate; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key accounts; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, including rising interest rates; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities; changing regulations or market conditions regarding environmental sustainability; our ability to retain key members of management and manage labor costs; work stoppages due to labor disputes; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers' products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

     
     
     

    AptarGroup, Inc.

    Condensed Consolidated Financial Statements (Unaudited)

    (In Thousands, Except Per Share Data)

    Consolidated Statements of Income 

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

     

     

    2024

     

     

     

     

     

    Net Sales

    $

    887,305

     

     

    $

    915,448

     

    Cost of Sales (exclusive of depreciation and amortization shown below)

     

    550,891

     

     

     

    582,756

     

    Selling, Research & Development and Administrative

     

    155,277

     

     

     

    152,780

     

    Depreciation and Amortization

     

    65,647

     

     

     

    64,349

     

    Restructuring Initiatives

     

    2,042

     

     

     

    3,480

     

    Operating Income

     

    113,448

     

     

     

    112,083

     

    Other Income (Expense):

     

     

     

    Interest Expense

     

    (11,351

    )

     

     

    (10,175

    )

    Interest Income

     

    2,814

     

     

     

    2,898

     

    Net Investment (Loss) Gain

     

    (1,096

    )

     

     

    592

     

    Equity in Results of Affiliates

     

    2,086

     

     

     

    (221

    )

    Miscellaneous Income, net

     

    114

     

     

     

    (859

    )

    Income before Income Taxes

     

    106,015

     

     

     

    104,318

     

    Provision for Income Taxes

     

    27,352

     

     

     

    21,385

     

    Net Income

    $

    78,663

     

     

    $

    82,933

     

    Net Loss Attributable to Noncontrolling Interests

     

    135

     

     

     

    171

     

    Net Income Attributable to AptarGroup, Inc.

    $

    78,798

     

     

    $

    83,104

     

    Net Income Attributable to AptarGroup, Inc. per Common Share:

     

     

     

    Basic

    $

    1.19

     

     

    $

    1.26

     

    Diluted

    $

    1.17

     

     

    $

    1.23

     

     

     

     

     

    Average Numbers of Shares Outstanding:

     

     

     

    Basic

     

    66,271

     

     

     

    66,064

     

    Diluted

     

    67,491

     

     

     

    67,432

     

     
     
     
     

    AptarGroup, Inc.

    Condensed Consolidated Financial Statements (Unaudited)

    (continued)

    ($ In Thousands)

    Consolidated Balance Sheets 

     

     

    March 31,

    2025

     

    December 31,

    2024

    ASSETS

     

     

     

     

     

     

     

    Cash and Equivalents

    $

    125,839

     

    $

    223,844

    Short-term Investments

     

    10,982

     

     

    2,337

    Accounts and Notes Receivable, Net

     

    742,703

     

     

    658,057

    Inventories

     

    483,520

     

     

    461,807

    Prepaid and Other

     

    148,723

     

     

    132,338

    Total Current Assets

     

    1,511,767

     

     

    1,478,383

    Property, Plant and Equipment, Net

     

    1,489,398

     

     

    1,447,150

    Goodwill

     

    954,292

     

     

    936,256

    Other Assets

     

    571,631

     

     

    570,489

    Total Assets

    $

    4,527,088

     

    $

    4,432,278

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

     

     

     

    Short-Term Obligations

    $

    445,386

     

    $

    338,285

    Accounts Payable, Accrued and Other Liabilities

     

    762,638

     

     

    729,996

    Total Current Liabilities

     

    1,208,024

     

     

    1,068,281

    Long-Term Obligations

     

    561,165

     

     

    688,066

    Deferred Liabilities and Other

     

    206,365

     

     

    190,007

    Total Liabilities

     

    1,975,554

     

     

    1,946,354

     

     

     

     

    AptarGroup, Inc. Stockholders' Equity

     

    2,537,558

     

     

    2,471,888

    Noncontrolling Interests in Subsidiaries

     

    13,976

     

     

    14,036

    Total Stockholders' Equity

     

    2,551,534

     

     

    2,485,924

     

     

     

     

    Total Liabilities and Stockholders' Equity

    $

    4,527,088

     

    $

    4,432,278

     
     
     
     

    AptarGroup, Inc.

    Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

    ($ In Thousands) 

     

     

    Three Months Ended

    March 31, 2025

     

     

     

    Consolidated

     

     

    Aptar Pharma

     

    Aptar Beauty

     

    Aptar Closures

     

    Corporate

    & Other

     

    Net Interest

    Net Sales

    $

    887,305

     

     

     

    $

    409,467

     

     

    $

    305,707

     

     

    $

    172,131

     

     

    $

    —

     

     

    $

    —

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Reported net income

    $

    78,663

     

     

     

     

     

     

     

     

     

     

     

     

    Reported income taxes

     

    27,352

     

     

     

     

     

     

     

     

     

     

     

     

    Reported income before income taxes

     

    106,015

     

     

     

     

    111,112

     

     

     

    16,681

     

     

     

    12,333

     

     

     

    (25,574

    )

     

     

    (8,537

    )

    Adjustments:

     

     

     

     

     

     

     

     

     

     

     

     

    Restructuring initiatives

     

    2,042

     

     

     

     

    190

     

     

     

    395

     

     

     

    1,352

     

     

     

    105

     

     

     

    Net investment loss

     

    1,096

     

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    1,096

     

     

     

    Adjusted earnings before income taxes

     

    109,153

     

     

     

     

    111,302

     

     

     

    17,076

     

     

     

    13,685

     

     

     

    (24,373

    )

     

     

    (8,537

    )

    Interest expense

     

    11,351

     

     

     

     

     

     

     

     

     

     

     

     

    11,351

     

    Interest income

     

    (2,814

    )

     

     

     

     

     

     

     

     

     

     

     

    (2,814

    )

    Adjusted earnings before net interest and taxes (Adjusted EBIT)

     

    117,690

     

     

     

     

    111,302

     

     

     

    17,076

     

     

     

    13,685

     

     

     

    (24,373

    )

     

     

    —

     

    Depreciation and amortization

     

    65,647

     

     

     

     

    31,148

     

     

     

    20,062

     

     

     

    13,575

     

     

     

    862

     

     

     

    Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

    $

    183,337

     

     

     

    $

    142,450

     

     

    $

    37,138

     

     

    $

    27,260

     

     

    $

    (23,511

    )

     

    $

    —

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Reported net income margins (Reported net income / Reported Net Sales)

     

    8.9

    %

     

     

     

     

     

     

     

     

     

     

     

    Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

     

    20.7

    %

     

     

     

    34.8

    %

     

     

    12.1

    %

     

     

    15.8

    %

     

     

     

     

     

    Three Months Ended

    March 31, 2024

     

     

     

    Consolidated

     

     

    Aptar Pharma

     

    Aptar Beauty

     

    Aptar Closures

     

    Corporate

    & Other

     

    Net Interest

    Net Sales

    $

    915,448

     

     

     

    $

    407,293

     

     

    $

    327,320

     

     

    $

    180,835

     

     

    $

    —

     

     

    $

    —

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Reported net income

    $

    82,933

     

     

     

     

     

     

     

     

     

     

     

     

    Reported income taxes

     

    21,385

     

     

     

     

     

     

     

     

     

     

     

     

    Reported income before income taxes

     

    104,318

     

     

     

     

    103,352

     

     

     

    17,196

     

     

     

    12,870

     

     

     

    (21,823

    )

     

     

    (7,277

    )

    Adjustments:

     

     

     

     

     

     

     

     

     

     

     

     

    Restructuring initiatives

     

    3,480

     

     

     

     

    24

     

     

     

    2,710

     

     

     

    760

     

     

     

    (14

    )

     

     

    Net investment gain

     

    (592

    )

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (592

    )

     

     

    Adjusted earnings before income taxes

     

    107,206

     

     

     

     

    103,376

     

     

     

    19,906

     

     

     

    13,630

     

     

     

    (22,429

    )

     

     

    (7,277

    )

    Interest expense

     

    10,175

     

     

     

     

     

     

     

     

     

     

     

     

    10,175

     

    Interest income

     

    (2,898

    )

     

     

     

     

     

     

     

     

     

     

     

    (2,898

    )

    Adjusted earnings before net interest and taxes (Adjusted EBIT)

     

    114,483

     

     

     

     

    103,376

     

     

     

    19,906

     

     

     

    13,630

     

     

     

    (22,429

    )

     

     

    —

     

    Depreciation and amortization

     

    64,349

     

     

     

     

    28,802

     

     

     

    21,228

     

     

     

    13,531

     

     

     

    788

     

     

     

    —

     

    Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

    $

    178,832

     

     

     

    $

    132,178

     

     

    $

    41,134

     

     

    $

    27,161

     

     

    $

    (21,641

    )

     

    $

    —

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Reported net income margins (Reported net income / Reported Net Sales)

     

    9.1

    %

     

     

     

     

     

     

     

     

     

     

     

    Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

     

    19.5

    %

     

     

     

    32.5

    %

     

     

    12.6

    %

     

     

    15.0

    %

     

     

     

     

     
     
     
     

    AptarGroup, Inc.

    Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)

    (In Thousands, Except Per Share Data) 

     

     

    Three Months Ended

    March 31,

     

    2025

     

    2024

     

     

     

     

    Income before Income Taxes

    $

    106,015

     

    $

    104,318

     

     

     

     

     

    Adjustments:

     

     

     

    Restructuring initiatives

     

    2,042

     

     

    3,480

     

    Net investment loss (gain)

     

    1,096

     

     

    (592

    )

    Foreign currency effects (1)

     

     

     

    (3,307

    )

    Adjusted Earnings before Income Taxes

    $

    109,153

     

    $

    103,899

     

     

     

     

     

    Provision for Income Taxes

    $

    27,352

     

    $

    21,385

     

     

     

     

     

    Adjustments:

     

     

     

    Restructuring initiatives

     

    506

     

     

    891

     

    Net investment loss (gain)

     

    269

     

     

    (145

    )

    Foreign currency effects (1)

     

     

     

    (678

    )

    Adjusted Provision for Income Taxes

    $

    28,127

     

    $

    21,453

     

     

     

     

     

    Net Loss Attributable to Noncontrolling Interests

    $

    135

     

    $

    171

     

     

     

     

     

    Net Income Attributable to AptarGroup, Inc.

    $

    78,798

     

    $

    83,104

     

     

     

     

     

    Adjustments:

     

     

     

    Restructuring initiatives

     

    1,536

     

     

    2,589

     

    Net investment loss (gain)

     

    827

     

     

    (447

    )

    Foreign currency effects (1)

     

     

     

    (2,629

    )

    Adjusted Net Income Attributable to AptarGroup, Inc.

    $

    81,161

     

    $

    82,617

     

     

     

     

     

    Average Number of Diluted Shares Outstanding

     

    67,491

     

     

    67,432

     

     

     

     

     

    Net Income Attributable to AptarGroup, Inc. Per Diluted Share

    $

    1.17

     

    $

    1.23

     

     

     

     

     

    Adjustments:

     

     

     

    Restructuring initiatives

     

    0.02

     

     

    0.04

     

    Net investment loss (gain)

     

    0.01

     

     

    (0.01

    )

    Foreign currency effects (1)

     

     

     

    (0.04

    )

    Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share

    $

    1.20

     

    $

    1.22

     

     

    (1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates. 

     
     
     
     

    AptarGroup, Inc.

    Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited)

    (In Thousands) 

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

     

     

    2024

     

     

     

     

     

    Net Cash Provided by Operations

    $

    82,742

     

     

    $

    92,333

     

    Capital Expenditures

     

    (56,862

    )

     

     

    (75,661

    )

    Free Cash Flow

    $

    25,880

     

     

    $

    16,672

     

     
     
     
     

    AptarGroup, Inc.

    Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)

    (In Thousands, Except Per Share Data) 

     

     

    Three Months Ending

    June 30,

     

    Expected 2025

     

     

    2024

     

     

     

     

     

    Income before Income Taxes

     

     

    $

    118,246

     

     

     

     

     

    Adjustments:

     

     

     

    Restructuring initiatives

     

     

     

    2,315

     

    Net investment loss

     

     

     

    140

     

    Transaction costs related to acquisitions

     

     

     

    140

     

    Foreign currency effects (1)

     

     

     

    (111

    )

    Adjusted Earnings before Income Taxes

     

     

    $

    120,730

     

     

     

     

     

    Provision for Income Taxes

     

     

    $

    27,788

     

     

     

     

     

    Adjustments:

     

     

     

    Restructuring initiatives

     

     

     

    567

     

    Net investment loss

     

     

     

    34

     

    Transaction costs related to acquisitions

     

     

     

    35

     

    Foreign currency effects (1)

     

     

     

    (26

    )

    Adjusted Provision for Income Taxes

     

     

    $

    28,398

     

     

     

     

     

    Net Loss Attributable to Noncontrolling Interests

     

     

    $

    (4

    )

     

     

     

     

    Net Income Attributable to AptarGroup, Inc.

     

     

    $

    90,454

     

     

     

     

     

    Adjustments:

     

     

     

    Restructuring initiatives

     

     

     

    1,748

     

    Net investment loss

     

     

     

    106

     

    Transaction costs related to acquisitions

     

     

     

    105

     

    Foreign currency effects (1)

     

     

     

    (85

    )

    Adjusted Net Income Attributable to AptarGroup, Inc.

     

     

    $

    92,328

     

     

     

     

     

    Average Number of Diluted Shares Outstanding

     

     

     

    67,575

     

     

     

     

     

    Net Income Attributable to AptarGroup, Inc. Per Diluted Share (3)

     

     

    $

    1.34

     

     

     

     

     

    Adjustments:

     

     

     

    Restructuring initiatives

     

     

     

    0.03

     

    Net investment loss

     

     

     

    —

     

    Transaction costs related to acquisitions

     

     

     

    —

     

    Foreign currency effects (1)

     

     

     

    —

     

    Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2)

    $1.56 - $1.64

     

    $

    1.37

     

     

    (1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current spot rates for all applicable foreign currency exchange rates. 

     

    (2) AptarGroup's expected earnings per share range for the second quarter of 2025, excluding any restructuring expenses, acquisition costs and changes in fair value of equity investments, is based on an effective tax rate range of 19% to 21%. This tax rate range compares to our second quarter of 2024 effective tax rate of 24% on reported earnings and adjusted earnings per share. 

     
     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250501642213/en/

    Investor Relations Contact:

    Mary Skafidas

    [email protected]

    815-479-5530

    Media Contact:

    Katie Reardon

    [email protected]

    815-479-5671

    Get the next $ATR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATR

    DatePrice TargetRatingAnalyst
    1/7/2025$200.00Outperform
    Raymond James
    1/6/2025$173.00Buy → Neutral
    BofA Securities
    10/14/2024$155.00 → $215.00Hold → Buy
    Jefferies
    4/29/2024Mkt Perform → Outperform
    William Blair
    1/3/2024$125.00 → $150.00Neutral → Outperform
    Robert W. Baird
    1/20/2022$150.00 → $126.00Equal-Weight
    Morgan Stanley
    12/22/2021$162.00 → $156.00Overweight
    Wells Fargo
    12/20/2021$148.00 → $145.00Buy
    Deutsche Bank
    More analyst ratings

    $ATR
    SEC Filings

    See more
    • SEC Form S-8 filed by AptarGroup Inc.

      S-8 - APTARGROUP, INC. (0000896622) (Filer)

      5/9/25 4:12:00 PM ET
      $ATR
      Plastic Products
      Industrials
    • AptarGroup Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - APTARGROUP, INC. (0000896622) (Filer)

      5/8/25 9:02:00 AM ET
      $ATR
      Plastic Products
      Industrials
    • SEC Form 10-Q filed by AptarGroup Inc.

      10-Q - APTARGROUP, INC. (0000896622) (Filer)

      5/2/25 10:29:49 AM ET
      $ATR
      Plastic Products
      Industrials

    $ATR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Glickman Sarah Js was granted 1,069 shares, increasing direct ownership by 53% to 3,076 units (SEC Form 4)

      4 - APTARGROUP, INC. (0000896622) (Issuer)

      5/9/25 9:28:24 AM ET
      $ATR
      Plastic Products
      Industrials
    • Chief Human Resources Officer Vinczeller Shiela sold $151,658 worth of shares (995 units at $152.42), decreasing direct ownership by 4% to 26,301 units (SEC Form 4)

      4 - APTARGROUP, INC. (0000896622) (Issuer)

      5/8/25 5:35:08 PM ET
      $ATR
      Plastic Products
      Industrials
    • Director Owens B Craig was granted 1,069 shares, increasing direct ownership by 12% to 9,757 units (SEC Form 4)

      4 - APTARGROUP, INC. (0000896622) (Issuer)

      5/8/25 5:29:42 PM ET
      $ATR
      Plastic Products
      Industrials

    $ATR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James initiated coverage on AptarGroup with a new price target

      Raymond James initiated coverage of AptarGroup with a rating of Outperform and set a new price target of $200.00

      1/7/25 9:09:40 AM ET
      $ATR
      Plastic Products
      Industrials
    • AptarGroup downgraded by BofA Securities with a new price target

      BofA Securities downgraded AptarGroup from Buy to Neutral and set a new price target of $173.00

      1/6/25 9:13:43 AM ET
      $ATR
      Plastic Products
      Industrials
    • AptarGroup upgraded by Jefferies with a new price target

      Jefferies upgraded AptarGroup from Hold to Buy and set a new price target of $215.00 from $155.00 previously

      10/14/24 7:25:09 AM ET
      $ATR
      Plastic Products
      Industrials

    $ATR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aptar Reports First Quarter 2025 Results

      AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following first quarter results for the period ended March 31, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501642213/en/Aptar Reports First Quarter 2025 Results First Quarter 2025 Highlights (compared to the prior year quarter) Reported sales of $887 million, a 3% decrease, and reported net income of $79 million, a 5% decrease Core sales were flat and adjusted EBITDA increased 3% from the prior year to $183 mill

      5/1/25 5:03:00 PM ET
      $ATR
      Plastic Products
      Industrials
    • Aptar Declares Quarterly Dividend

      AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share. The payment date is May 22, 2025, to stockholders of record as of May 1, 2025. As previously announced, Aptar will hold a conference call on Friday, May 2, 2025 at 8:00 a.m. Central Time to discuss the Company's first quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website. About Aptar

      4/17/25 5:00:00 PM ET
      $ATR
      Plastic Products
      Industrials
    • Aptar Announces Clinical Validation Study to Accelerate US FDA Approval of SmartTrack™ In-Vitro-in-Silico Platform for Pressurized Metered-Dose Inhalers

      SmartTrack™ aims to reduce the need for clinical studies in generic drug product approvals AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announces the commencement of a clinical study to validate its proprietary SmartTrack™ platform. The platform was developed by Aptar's drug services company, Nanopharm. If validated, SmartTrack™ aims to reduce the need for clinical studies in generic drug product approvals by proving it can accurately predict clinical outcomes – removing a major barrier for pharma companies and regulators and paving the way for wider patient access to medications. This validation would estab

      4/16/25 8:00:00 AM ET
      $ATR
      Plastic Products
      Industrials

    $ATR
    Financials

    Live finance-specific insights

    See more
    • Aptar Reports First Quarter 2025 Results

      AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following first quarter results for the period ended March 31, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501642213/en/Aptar Reports First Quarter 2025 Results First Quarter 2025 Highlights (compared to the prior year quarter) Reported sales of $887 million, a 3% decrease, and reported net income of $79 million, a 5% decrease Core sales were flat and adjusted EBITDA increased 3% from the prior year to $183 mill

      5/1/25 5:03:00 PM ET
      $ATR
      Plastic Products
      Industrials
    • Aptar Declares Quarterly Dividend

      AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share. The payment date is May 22, 2025, to stockholders of record as of May 1, 2025. As previously announced, Aptar will hold a conference call on Friday, May 2, 2025 at 8:00 a.m. Central Time to discuss the Company's first quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website. About Aptar

      4/17/25 5:00:00 PM ET
      $ATR
      Plastic Products
      Industrials
    • Aptar Reports Fourth Quarter and Annual 2024 Results

      AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong fourth quarter results due to solid operational performance driven by top and bottom line improvements. Results were driven by sales growth in pharma solutions, increased demand for closures technologies and productivity gains across the company. Reported sales increased by 1% and core sales increased by 2% due to a negative currency effect. Aptar reported net income of $101 million for the quarter, a 62% increase from the prior year. In addition, the quarterly results benefited from a lower effective tax rate. This press release features multimedi

      2/6/25 5:17:00 PM ET
      $ATR
      Plastic Products
      Industrials

    $ATR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AptarGroup Inc. (Amendment)

      SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)

      2/13/24 4:58:57 PM ET
      $ATR
      Plastic Products
      Industrials
    • SEC Form SC 13G/A filed by AptarGroup Inc. (Amendment)

      SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)

      2/12/24 3:08:10 PM ET
      $ATR
      Plastic Products
      Industrials
    • SEC Form SC 13G/A filed by AptarGroup Inc. (Amendment)

      SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)

      2/12/24 11:53:37 AM ET
      $ATR
      Plastic Products
      Industrials

    $ATR
    Leadership Updates

    Live Leadership Updates

    See more
    • Aptar CFO, Robert (Bob) Kuhn, Has Decided to Step Down After 37 Years with the Company

      Aptar Names Vanessa Kanu, A Finance Veteran with Over 25 Years of Experience, as Next CFO AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Bob Kuhn, Executive Vice President and Chief Financial Officer (CFO) since 2008, has decided to retire at the end of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725873916/en/(Left to right) Bob Kuhn, Executive Vice President and Chief Financial Officer since 2008, has decided to retire at the end of 2024; Vanessa Kanu will become Executive Vice President and CFO on January 1, 2025,

      7/25/24 5:20:00 PM ET
      $ATR
      Plastic Products
      Industrials
    • Aptar Appoints Global Finance and Operations Veteran Sarah Glickman to its Board of Directors

      AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Sarah Glickman, an accomplished leader with more than 30 years of global financial and operational experience, has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905451175/en/Sarah Glickman Joins Aptar's Board of Directors (Photo: Aptar) "We are pleased to welcome Sarah Glickman to our Board of Directors. Sarah's extensive knowledge of all aspects of corporate finance coupled with her global operational experience, including in the pharmaceutical industry

      9/5/23 5:00:00 PM ET
      $ATR
      Plastic Products
      Industrials
    • Aptar Appoints Julie Xing to its Board of Directors

      AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Julie Xing has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230220005172/en/Julie Xing Joins Aptar's Board of Directors (Photo: Aptar) With over 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis, Julie's leadership approach focuses on inspiring teams to deliver sustainable growth in challenging markets and healthcare environments. With her solid track record of business transformation in multiple g

      3/1/23 5:00:00 PM ET
      $ATR
      Plastic Products
      Industrials